OncoTargets and therapy最新文献

筛选
英文 中文
Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma. 免疫疗法对秘鲁晚期黑色素瘤患者生存期的影响及生物标志物评估。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-11-02 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S483753
Guillermo Valencia, Katia Roque, Patricia Rioja, José Andrés Huamán, Valeria Colomo, Jorge Sánchez, Cindy Calle, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Tatiana Vidaurre, Silvia Neciosup, Ramon Andrade De Mello, Henry L Gómez, Amaya B Fernández-Díaz, Alfonso Berrocal, Carlos Castaneda
{"title":"Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.","authors":"Guillermo Valencia, Katia Roque, Patricia Rioja, José Andrés Huamán, Valeria Colomo, Jorge Sánchez, Cindy Calle, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Tatiana Vidaurre, Silvia Neciosup, Ramon Andrade De Mello, Henry L Gómez, Amaya B Fernández-Díaz, Alfonso Berrocal, Carlos Castaneda","doi":"10.2147/OTT.S483753","DOIUrl":"10.2147/OTT.S483753","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced malignant melanoma is a very aggressive disease, historically with poor prognosis before the new advances with immunotherapy and targeted therapies that have changed the standard of care, especially in cutaneous melanoma. Peru has aggressive features such as higher rates of acral lentiginous melanoma (ALM) subtype with historically shorter survival.</p><p><strong>Methods: </strong>This study describes Peruvian patients with advanced melanoma treated with immunotherapy (nivolumab) in two oncological institutions (public and private), including the discussion of the impact on overall survival (OS) divided by subtype (with incidence in ALM histology) and potential biomarkers that could be related to prognosis.</p><p><strong>Results: </strong>We found that immunotherapy is safe, and improves progression-free survival (PFS), OS and objective response rate (ORR) in our patients, with lower benefit in ALM histology. No prognostic blood inflammatory biomarkers were detected.</p><p><strong>Discussion: </strong>There is very limited data of Peruvian patients with metastatic melanoma treated with immunotherapy, especially the outcomes in ALM histology. Our goal is to share an example of the impact of immunotherapy in a Latin American (LATAM) population considered as an unsatisfied group with an enormous need of novel treatments and biomarkers.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"871-886"},"PeriodicalIF":2.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tepotinib in Cholangiocarcinoma with MET Amplification: A Case Report. 特泊替尼治疗伴有 MET 扩增的胆管癌:病例报告。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S483155
Yen-Hao Chen, Yu-Ting Huang, Fang-Ying Kuo
{"title":"Tepotinib in Cholangiocarcinoma with MET Amplification: A Case Report.","authors":"Yen-Hao Chen, Yu-Ting Huang, Fang-Ying Kuo","doi":"10.2147/OTT.S483155","DOIUrl":"10.2147/OTT.S483155","url":null,"abstract":"<p><p>Cholangiocarcinoma is a malignant tumor that affects the bile ducts and is usually aggressive with poor prognosis. The treatment of cholangiocarcinoma depends on the stage and location of the tumor as well as the patient's overall health status. Systemic therapy, such as chemotherapy using gemcitabine and cisplatin, is the first choice for patients with cholangiocarcinoma who were inoperable. After no response to first-line chemotherapy, second-line chemotherapy or targeted therapy focusing on signaling pathway inhibition are subsequent treatment. The present report described a case of cholangiocarcinoma involving bilateral lobes of liver. He received one cycle of chemotherapy with gemcitabine plus cisplatin and exhibited rapid progression. Next-generation sequencing was performed, and the results showed that MET amplification had a gene copy number of 68. After that, he underwent tepotinib and tumor shrinkage occurred. After a follow‑up period of 12 months, the treatment response was partial response, and the benefit of tepotinib is ongoing. The development of precision medicine has expanded the paradigm of targeted therapies to increasingly favorable options in the second line and beyond, and prolong overall survival. Detecting druggable mutations (mutations potentially amenable to treatment with) for identifying a landscape of therapeutic options is imperative for managing cholangiocarcinoma.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"857-861"},"PeriodicalIF":2.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients. 局部晚期头颈癌患者吸入氢气的试点可行性和安全性研究
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S478613
Imjai Chitapanarux, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Narongchai Autsavapromporn, Tapanut Ariyanon, Junji Akagi, Akira Mizoo
{"title":"Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients.","authors":"Imjai Chitapanarux, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Narongchai Autsavapromporn, Tapanut Ariyanon, Junji Akagi, Akira Mizoo","doi":"10.2147/OTT.S478613","DOIUrl":"10.2147/OTT.S478613","url":null,"abstract":"<p><strong>Purpose: </strong>Hydrogen (H<sub>2</sub>) gas inhalation might alleviate acute radiotherapy toxicities by scavenging free radicals produced by ionizing radiation and anti-inflammatory properties. This study aimed to investigate the feasibility and safety of H<sub>2</sub> gas inhalation during concurrent chemoradiotherapy (CCRT) in patients with locally advanced head and neck cancer (LAHNC).</p><p><strong>Patients and methods: </strong>We designed a pilot prospective study combining CCRT with aerosol inhalation of H<sub>2</sub> gas. Each patient was scheduled to receive daily intensity-modulated radiotherapy (IMRT) in 33 fractions on a weekday and six cycles of weekly chemotherapy. All patients inhaled H<sub>2</sub> gas through a cannula or mask 1 hour per day, 1-2 hours before IMRT. The primary endpoint was the feasibility of H<sub>2</sub> inhalation. Eighty percent of the patients who completed at least 20 applications of H<sub>2</sub> gas inhalation were considered feasible. The secondary endpoints were safety profiles during H<sub>2</sub> gas inhalation (vital signs and symptoms related to H<sub>2</sub> gas inhalation) and acute toxicities during CCRT.</p><p><strong>Results: </strong>We enrolled 10 patients with LAHNC between July 2023 and December 2023. All patients received 33 fractions of H<sub>2</sub> gas inhalation on the same day as the IMRT. Vital signs during and at the end of H<sub>2</sub> gas inhalation were stable in all patients. None of the 10 patients had hypertension or hypotension during any of the 33 inhalations. No adverse events related to H<sub>2</sub> gas inhalation, such as cough, nasal bleeding, dizziness, headache, nausea, or vomiting, were reported. Grade 3 leukopenia was found in two patients (20%) during the 5th week of CCRT. Grade 2 radiation dermatitis and pharyngitis were found in three patients (30%).</p><p><strong>Conclusion: </strong>H<sub>2</sub> gas inhalation combined with CCRT is feasible and safe for patients with LAHNC.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"863-870"},"PeriodicalIF":2.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Potential Biomarkers and Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma Based on Bioinformatics. 基于生物信息学探索皮肤鳞状细胞癌的潜在生物标记物和分子机制
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-26 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S468399
Jiayue Qi, Qingqing Guo, Jia Bai, Xiaoqiang Liang, Wenwei Zhu, Chengxin Li, Fang Xie
{"title":"Exploring Potential Biomarkers and Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma Based on Bioinformatics.","authors":"Jiayue Qi, Qingqing Guo, Jia Bai, Xiaoqiang Liang, Wenwei Zhu, Chengxin Li, Fang Xie","doi":"10.2147/OTT.S468399","DOIUrl":"10.2147/OTT.S468399","url":null,"abstract":"<p><strong>Purpose: </strong>Cutaneous squamous cell carcinoma (cSCC) ranks as the second most common malignancy in clinical practice and poses a significant threat to public health due to its high malignancy. In this study, we aimed to explore potential biomarkers and molecular mechanisms of cSCC.</p><p><strong>Methods: </strong>Differentially expressed genes (DEGs) from GSE66359 and GSE117247 datasets were identified using R software. We conducted enrichment analyses and screened hub genes through protein-protein interaction (PPI) analysis and weighted gene co-expression network analysis (WGCNA). To assess the diagnostic performance of these genes, we generated ROC curves using both internal and external datasets (GSE45164) and validated the expression levels of these genes in cSCC tissues through immunohistochemistry. Subsequently, we predicted the target miRNAs and lncRNAs for hub genes using online databases and constructed competing endogenous RNA (ceRNA) networks.</p><p><strong>Results: </strong>In total, we identified 505 upregulated DEGs and 522 downregulated DEGs. Through PPI and WGCNA analyses, we identified four hub genes exhibiting robust diagnostic performance in internal and external datasets (AUC > 0.9) and selected three previously unreported genes for further analysis. Immunohistochemistry demonstrated significantly elevated CCNA2, CCNB2, and UBE2C expression in cSCC tissues compared to normal skin tissues. Finally, we constructed three ceRNA networks, namely NEAT1/H19-hsa-miR-148a-3p-CCNA2 and NEAT1-hsa-miR-140-3p-UBE2C.</p><p><strong>Conclusion: </strong>In conclusion, we have identified CCNA2, CCNB2, and UBE2C as novel biomarkers for cSCC, and the NEAT1/H19-hsa-miR-148a-3p-CCNA2 and NEAT1-hsa-miR-140-3p-UBE2C ceRNA networks may represent molecular mechanisms under-lying cSCC progression. The findings of this study offer new diagnostic and therapeutic options for cSCC patients.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"841-856"},"PeriodicalIF":2.7,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytotoxic Evaluation, Molecular Docking, Molecular Dynamics, and ADMET Prediction of Isolupalbigenin Isolated from Erythrina subumbrans (Hassk). Merr. (Fabaceae) Stem Bark: Unveiling Its Anticancer Efficacy. 从 Erythrina subumbrans (Hassk).Merr.(豆科)茎皮中分离出的 Isolupalbigenin:揭示其抗癌功效。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-17 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S482469
Tati Herlina, Abd Wahid Rizaldi Akili, Vicki Nishinarizki, Ari Hardianto, Allyn Pramudya Sulaeman, Shabarni Gaffar, Euis Julaeha, Tri Mayanti, Unang Supratman, Mohd Azlan Nafiah, Jalifah Binti Latip
{"title":"Cytotoxic Evaluation, Molecular Docking, Molecular Dynamics, and ADMET Prediction of Isolupalbigenin Isolated from <i>Erythrina subumbrans</i> (Hassk). Merr. (Fabaceae) Stem Bark: Unveiling Its Anticancer Efficacy.","authors":"Tati Herlina, Abd Wahid Rizaldi Akili, Vicki Nishinarizki, Ari Hardianto, Allyn Pramudya Sulaeman, Shabarni Gaffar, Euis Julaeha, Tri Mayanti, Unang Supratman, Mohd Azlan Nafiah, Jalifah Binti Latip","doi":"10.2147/OTT.S482469","DOIUrl":"10.2147/OTT.S482469","url":null,"abstract":"<p><strong>Introduction: </strong><i>Erythrina subumbrans</i>, a medical plant found in sub-Saharan Africa and the Western Ghats of India, shows promise as a potential source of bioactive compounds to treat cancer. In our ongoing research on folk medical plants, we report the isolation of flavonoid compound from the stem bark of <i>E. subumbrans</i> along with its cytotoxic activity against breast cancer (MCF-7 and T47D), and cervical cancer (HeLa) cell lines.</p><p><strong>Purpose: </strong>This study aimed to isolate secondary metabolite from the stem bark of <i>E. subumbrans</i> and evaluate its cytotoxic activity to support the use of folk medicinal plants as alternative therapy against cancer.</p><p><strong>Methods: </strong>Isolupalbigenin was isolated from the stem bark of <i>E. subumbrans</i> by column chromatography. Cytotoxic activity against breast cancer (MCF-7 and T47D) and cervical cancer (HeLa) cell lines was evaluated using the MTT assay, whereas the in silico study was evaluated using molecular docking and molecular dynamics against estrogen receptor alpha (ERα).</p><p><strong>Results: </strong>The cytotoxic assay showed that isolupalbigenin inhibited the growth of MCF-7 cell with an IC<sub>50</sub> of 31.62 µg∙mL<sup>-1</sup>, while showing no toxicity against normal human cells (Vero cell line). The molecular docking results suggested that isolupalbigenin can bind to ERα with a lower binding affinity than estradiol, whereas the stability of the isolupalbigenin-ERα complex was confirmed by molecular dynamic simulation with a median Root Mean Square Deviation (RMSD) of 2.80 Å. Toxicity prediction suggested that isolupalbigenin was less likely to cause hepatotoxicity or carcinogenicity, whereas pharmacokinetic prediction suggested that isolupalbigenin has high intestinal absorption with medium Caco2 permeability. In addition, isolupalbigenin was predicted to have a medium volume of distribution (Vd).</p><p><strong>Conclusion: </strong>Isolupalbigenin isolated from the stem bark of <i>E. subumbrans</i> with cytotoxic activity supports further development of plants from the genus <i>Erythrina</i> as a medicinal plant for alternative therapy against cancer.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"829-840"},"PeriodicalIF":2.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy and Breast Cancer: A Challenge for the Multidisciplinary Team. A Single Center Experience and Narrative Review. 妊娠与乳腺癌:多学科团队面临的挑战。单中心经验与叙事回顾。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S464860
Fiorella Ruatta, Nerina Denaro, Paola Vanella, Gianluca Tomasello, Ernesto Principe, Grazia Sciancalepore, Carmen Giusy Rea, Ornella Garrone
{"title":"Pregnancy and Breast Cancer: A Challenge for the Multidisciplinary Team. A Single Center Experience and Narrative Review.","authors":"Fiorella Ruatta, Nerina Denaro, Paola Vanella, Gianluca Tomasello, Ernesto Principe, Grazia Sciancalepore, Carmen Giusy Rea, Ornella Garrone","doi":"10.2147/OTT.S464860","DOIUrl":"https://doi.org/10.2147/OTT.S464860","url":null,"abstract":"<p><strong>Purpose: </strong>The diagnosis of breast cancer during pregnancy is a rare event, but it is more frequent in our daily clinical practice due to the progressing aging of pregnant women. The management of a woman affected by pregnancy-associated breast cancer (PABC) remains a challenge for the clinician as it is related to ethical and psychological decisions.</p><p><strong>Patients and methods: </strong>Here, we retrospectively described 10 cases of PABC in women treated at our Institution. All cases were discussed in the multidisciplinary team. We reviewed available literature data on the topic.</p><p><strong>Results: </strong>Nine out 10 patients were diagnosed with localized breast cancer. The remaining patients were presented with metastatic de novo disease. Median age was 37.5 years (range 26-42). Seven patients presented with grade 3 tumor and 9 patients had Ki-67 value higher than 30%. All but 2 patients received neoadjuvant chemotherapy consisting of sequential anthracyclines and cyclophosphamide followed by weekly paclitaxel during pregnancy. No safety concerns or complications during delivery for both the mothers and the babies were reported.</p><p><strong>Conclusion: </strong>Breast cancer during pregnancy is a challenging clinical situation and all the decisions need to consider both the patients and the fetus safety. Data from our series and from literature confirm the safety of standard chemotherapy approach starting from the second trimester of gestation. More research and effort are needed to offer these patients excellent outcomes and it is mandatory that cases should be closely followed up by a multidisciplinary team.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"821-827"},"PeriodicalIF":2.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA PTPRG-AS1 Promotes Breast Cancer Progression by Modulating the miR-4659a-3p/QPCT Axis. LncRNA PTPRG-AS1 通过调节 miR-4659a-3p/QPCT 轴促进乳腺癌进展
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S474898
Mengsi Zhou, Yanting Li, Liu Yang, Shuo Liu, Lixian Yang, Bin Xu, Xiaolong Li, Quanle Wang, Haijun Zhao, Zhenchuan Song
{"title":"LncRNA PTPRG-AS1 Promotes Breast Cancer Progression by Modulating the miR-4659a-3p/QPCT Axis.","authors":"Mengsi Zhou, Yanting Li, Liu Yang, Shuo Liu, Lixian Yang, Bin Xu, Xiaolong Li, Quanle Wang, Haijun Zhao, Zhenchuan Song","doi":"10.2147/OTT.S474898","DOIUrl":"https://doi.org/10.2147/OTT.S474898","url":null,"abstract":"<p><strong>Background: </strong>Overwhelming evidence has suggested that dysregulated long noncoding RNAs (lncRNAs) play a critical modulating effect in the evolution of breast cancer (BRCA). Nevertheless, the roles of lncRNA PTPRG antisense RNA 1 (PTPRG-AS1) in BRCA and the underlying mechanisms have not been experimentally validated and functionally annotated.</p><p><strong>Methods: </strong>The expression of lncRNA PTPRG-AS1 in BRCA tissues and cell lines was evaluated by reverse transcription-quantitative PCR (RT-qPCR), and by using public databases. The proliferation of BRCA cells was detected using Cell Counting Kit-8 and colony formation assays. Wound healing assay, and Transwell migration and invasion assays were carried out to explore the migratory and invasive abilities of BRCA cells. The interaction between lncRNA PTPRG-AS1, microRNA (miR)-4659a-3p and glutaminyl-peptide cyclotransferase (QPCT) was verified using RT-qPCR, dual-luciferase reporter assay and Western blotting.</p><p><strong>Results: </strong>The results showed that LncRNA PTPRG-AS1 was markedly upregulated in BRCA tissues and cell lines. Knocking down lncRNA PTPRG-AS1 significantly inhibited the proliferation, migration and invasion of BRCA cells, while overexpression of lncRNA PTPRG-AS1 enhanced the aforementioned properties of BRCA cells. Further analyses revealed that PTPRG-AS1 may act as a molecular sponge for miR-4659a-3p, thus regulating QPCT expression, therefore, acting as an oncogene in BRCA.</p><p><strong>Conclusion: </strong>Collectively, the study demonstrates that lncRNA PTPRG-AS1 may act as a competing endogenous RNA by regulating the miR-4659a-3p/QPCT axis in BRCA progression. This lncRNA could potentially be a biomarker and therapeutic target for BRCA.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"805-819"},"PeriodicalIF":2.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Synergism from the Combination of Ulinastatin and Curcumin Offers Greater Inhibition against Colorectal Cancer Liver Metastases via Modulating Matrix Metalloproteinase-9 and E-Cadherin Expression [Corrigendum]. 勘误:乌利司他汀与姜黄素联用可通过调节基质金属蛋白酶-9和E-Cadherin的表达对结直肠癌肝转移产生更大的抑制作用[更正]。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S493466
{"title":"Erratum: Synergism from the Combination of Ulinastatin and Curcumin Offers Greater Inhibition against Colorectal Cancer Liver Metastases via Modulating Matrix Metalloproteinase-9 and E-Cadherin Expression [Corrigendum].","authors":"","doi":"10.2147/OTT.S493466","DOIUrl":"https://doi.org/10.2147/OTT.S493466","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/OTT.S57126.].</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"803-804"},"PeriodicalIF":2.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment. 晚期宫颈癌检测、预防和治疗的治疗策略。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S475132
Xolisiwe M Sebutsoe, Nrateng Joyful Nonhlanzeko Tsotetsi, Zodwa Edith Jantjies, Portia Pheladi Raphela-Choma, Mpho S Choene, Lesetja R Motadi
{"title":"Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.","authors":"Xolisiwe M Sebutsoe, Nrateng Joyful Nonhlanzeko Tsotetsi, Zodwa Edith Jantjies, Portia Pheladi Raphela-Choma, Mpho S Choene, Lesetja R Motadi","doi":"10.2147/OTT.S475132","DOIUrl":"https://doi.org/10.2147/OTT.S475132","url":null,"abstract":"<p><p>Cervical cancer is ranked the fourth most common cause of cancer related deaths amongst women. The situation is particularly dire in low to lower middle-income countries. It continues to affect these countries due to poor vaccine coverage and screening. Cervical cancer is mostly detected in the advanced stages leading to poor outcomes. This review focuses on the progress made to date to improve early detection and targeted therapy using both circulating RNA. Vaccine has played a major role in cervical cancer control in vaccinated young woman in mainly developed countries yet in low-income countries with challenges of 3 dose vaccination affordability, cervical cancer continues to be the second most deadly amongst women. In this review, we show the progress made in reducing cervical cancer using vaccination that in combination with other treatments that might improve survival in cervical cancer. We further show with both miRNA and siRNA that targeted therapy and specific markers might be ideal for early detection of cervical cancer in low-income countries. These markers are either upregulated or down regulated in cancer providing clue to the stage of the cancer.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"785-801"},"PeriodicalIF":2.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Structurally Rare EML4-ALK Identified by Next Generation Sequencing in a Patient with NSCLC with Bilateral Ovarian Metastases. 病例报告:通过新一代测序在一名伴有双侧卵巢转移的 NSCLC 患者中发现结构罕见的 EML4-ALK。
IF 2.7 4区 医学
OncoTargets and therapy Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI: 10.2147/OTT.S474134
Ryusuke Maruta, Daichi Sadato, Makiko Yomota, Ryu Gomikawa, Toru Motoi, Tatsuya Sato, Nao Kino, Masayoshi Kobayashi, Yukio Hosomi
{"title":"Case Report: Structurally Rare <i>EML4-ALK</i> Identified by Next Generation Sequencing in a Patient with NSCLC with Bilateral Ovarian Metastases.","authors":"Ryusuke Maruta, Daichi Sadato, Makiko Yomota, Ryu Gomikawa, Toru Motoi, Tatsuya Sato, Nao Kino, Masayoshi Kobayashi, Yukio Hosomi","doi":"10.2147/OTT.S474134","DOIUrl":"https://doi.org/10.2147/OTT.S474134","url":null,"abstract":"<p><p>The <i>EML4-ALK</i> oncogene is a fusion of the <i>EML4</i> and <i>ALK</i> genes and is found in approximately 5-6% of the cases of non-small cell lung cancer (NSCLC). Herein, we present a unique case of lung adenocarcinoma with metastases to the bilateral ovaries harboring a rare <i>EML4-ALK</i> fusion gene variant in a 52-year-old patient. The patient had initially received a diagnosis of ovarian cancer, then had undergone neo-adjuvant chemotherapy followed by a surgical resection. Despite two cycles of adjuvant chemotherapy consisting of carboplatin and gemcitabine, CT revealed that the pleural effusion had increased from it before chemotherapy, and the shortness of breath worsened. Molecular profiling revealed an <i>EML4-ALK</i> rearrangement containing <i>ALK -EML4</i> and <i>ALK -NPR2</i> fusion genes. The diagnosis was changed to primary lung adenocarcinoma with metastases to the bilateral ovaries based on a pathological reevaluation. Treatment with alectinib, a second-generation ALK-tyrosine kinase inhibitor, led to a partial response of 18 months' duration, and the shortness of breath improved. No adverse events related to the alectinib therapy occurred. To assess the unique structure of the fusion genes, RNA sequencing was performed. An intronic sequence from both <i>ALK</i> and <i>EML4</i> was found between <i>ALK</i> and <i>EML4</i> exon, possibly because of an unusual insertion of a gene fragment derived from <i>NRP2</i>, indicated by the panel sequencing results. Variations in the drug response among <i>EML4-ALK</i> fusion variants highlight the importance of understanding their molecular structure. Further investigation is warranted to refine fusion gene detection methods and assess the therapeutic implications of rare fusion variants.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"777-783"},"PeriodicalIF":2.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11430267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信